New hope for tough liver cancer: adding chemo to immunotherapy shows promise
NCT ID NCT05198609
First seen Jan 25, 2026 · Last updated May 16, 2026 · Updated 19 times
Summary
This study tests whether adding a liver-directed chemotherapy infusion (FOLFOX-HAIC) to a two-drug immunotherapy regimen (camrelizumab plus apatinib) helps people with advanced liver cancer that has invaded the portal vein live longer. About 214 adults who have not had prior systemic treatment are being randomly assigned to one of the two treatment groups. The main goal is to see if the triple combination improves overall survival compared to the two-drug combination alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Center Sun Yat-sen University
Guangzhou, Guangdong, 510060, China
Conditions
Explore the condition pages connected to this study.